A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2015

At a glance

  • Drugs Denosumab (Primary)
  • Indications Bone resorption; Fracture; Male osteoporosis
  • Focus Registrational; Therapeutic Use
  • Acronyms HALT
  • Sponsors Amgen
  • Most Recent Events

    • 08 May 2014 Trial status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Sep 2012 Responder analysis published in Prostate Cancer and Prostatic Diseases.
    • 01 Dec 2011 Analysis assessing the effect of treatment on bone marker turnover levels published in the Journal of Bone and Mineral Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top